Literature DB >> 32086691

The Dual-Targeting Activity of the Metabolite Substrate of Para-amino Salicyclic Acid in the Mycobacterial Folate Pathway: Atomistic and Structural Perspectives.

Clement Agoni1, Pritika Ramharack1, Elliasu Y Salifu1, Mahmoud E S Soliman2.   

Abstract

Therapeutic targeting of folate biosynthetic pathway has recently been explored as a viable strategy in the treatment of tuberculosis. The bioactive metabolite substrate of Para-amino salicyclic acid (PAS-M) reportedly dual-targets dihydrofolate reductase (DHFR) and flavin-dependent thymidylate synthase (FDTS), two essential enzymes in folate biosynthetic pathway. However, the molecular mechanisms and structural dynamics of this dual inhibitory activity of the PAS-M remain elusive. Molecular dynamics simulations revealed that binding of PAS-M towards DHFR is characterized by a recurrence of strong conventional hydrogen bond interactions between a peculiar DHFR binding site residue (Asp27) and the 2-amino-decahydropteridin-4-ol group of PAS-M. Similarly, the binding of PAS-M towards FDTS also involved consistent strong conventional hydrogen bond interactions between some specific residues (Tyr101, Arg172, Thr4, Gln103, Arg87 and Gln106) and, the 2-amino-decahydropteridin-4-ol group, thus establishing the cruciality of the group. Structural dynamics of the bound complexes of both enzymes revealed that, upon binding, PAS-M is anchored at the entrance of hydrophobic pockets by strong hydrogen bond interactions while the rest of the structure gains access to deeper hydrophobic residues to engage in favorable interactions. Further analysis of atomistic changes of both enzymes showed increased C-α atom deviations as well as an increase C-α atoms radius of gyration consistent with structural disorientations. These conformational changes possibly interfered with the biological functions of the enzymes and hence their inhibition as experimentally reported. Structural Insights provided could open up a novel paradigm of structure-based design of multi-targeting inhibitors of biological targets in the folate biosynthetic pathway toward tuberculosis therapy.

Entities:  

Keywords:  Dihydrofolate reductase; Flavin-dependent thymidine synthase; Folate biosynthetic pathway; Molecular dynamics simulation; Mycobacterium tuberculosis; Tuberculosis

Year:  2020        PMID: 32086691     DOI: 10.1007/s10930-020-09885-1

Source DB:  PubMed          Journal:  Protein J        ISSN: 1572-3887            Impact factor:   2.371


  41 in total

1.  UCSF Chimera--a visualization system for exploratory research and analysis.

Authors:  Eric F Pettersen; Thomas D Goddard; Conrad C Huang; Gregory S Couch; Daniel M Greenblatt; Elaine C Meng; Thomas E Ferrin
Journal:  J Comput Chem       Date:  2004-10       Impact factor: 3.376

2.  Drugging the Folate Pathway in Mycobacterium tuberculosis: The Role of Multi-targeting Agents.

Authors:  Behnoush Hajian; Eric Scocchera; Carolyn Shoen; Jolanta Krucinska; Kishore Viswanathan; Narendran G-Dayanandan; Heidi Erlandsen; Alexavier Estrada; Katarína Mikušová; Jana Korduláková; Michael Cynamon; Dennis Wright
Journal:  Cell Chem Biol       Date:  2019-03-28       Impact factor: 8.116

3.  AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading.

Authors:  Oleg Trott; Arthur J Olson
Journal:  J Comput Chem       Date:  2010-01-30       Impact factor: 3.376

Review 4.  Antibiotic resistance mechanisms in M. tuberculosis: an update.

Authors:  Liem Nguyen
Journal:  Arch Toxicol       Date:  2016-05-09       Impact factor: 5.153

5.  Co-inhibition as a strategic therapeutic approach to overcome rifampin resistance in tuberculosis therapy: atomistic insights.

Authors:  Clement Agoni; Pritika Ramharack; Mahmoud Es Soliman
Journal:  Future Med Chem       Date:  2018-06-29       Impact factor: 3.808

6.  Structure of the Mycobacterium tuberculosis flavin dependent thymidylate synthase (MtbThyX) at 2.0A resolution.

Authors:  Parthasarathy Sampathkumar; Stewart Turley; Jonathan E Ulmer; Ho Gun Rhie; Carol Hopkins Sibley; Wim G J Hol
Journal:  J Mol Biol       Date:  2005-10-07       Impact factor: 5.469

7.  Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis.

Authors:  Daphne Yee; Chantal Valiquette; Marthe Pelletier; Isabelle Parisien; Isabelle Rocher; Dick Menzies
Journal:  Am J Respir Crit Care Med       Date:  2003-01-31       Impact factor: 21.405

8.  Across the blood-brain barrier: Neurotherapeutic screening and characterization of naringenin as a novel CRMP-2 inhibitor in the treatment of Alzheimer's disease using bioinformatics and computational tools.

Authors:  Maryam Lawal; Fisayo A Olotu; Mahmoud E S Soliman
Journal:  Comput Biol Med       Date:  2018-05-16       Impact factor: 4.589

Review 9.  Treatment of Tuberculous Meningitis and Its Complications in Adults.

Authors:  Angharad Davis; Graeme Meintjes; Robert J Wilkinson
Journal:  Curr Treat Options Neurol       Date:  2018-02-28       Impact factor: 3.598

Review 10.  Addressing the Challenges of Tuberculosis: A Brief Historical Account.

Authors:  Hussam W Al-Humadi; Rafal J Al-Saigh; Ahmed W Al-Humadi
Journal:  Front Pharmacol       Date:  2017-09-26       Impact factor: 5.810

View more
  2 in total

1.  Battling BTK mutants with noncovalent inhibitors that overcome Cys481 and Thr474 mutations in Waldenström macroglobulinemia therapy: structural mechanistic insights on the role of fenebrutinib.

Authors:  Ghazi Elamin; Aimen Aljoundi; Mohamed Issa Alahmdi; Nader E Abo-Dya; Mahmoud E S Soliman
Journal:  J Mol Model       Date:  2022-10-12       Impact factor: 2.172

2.  A combination screening to identify enhancers of para-aminosalicylic acid against Mycobacterium tuberculosis.

Authors:  Jinyeong Heo; Dahae Koh; Vincent Delorme; Minjeong Woo; Doyoon Kwon; Virgínia Carla de Almeida Falcão; Connor Wood; Honggun Lee; Kideok Kim; Inhee Choi; Jichan Jang; Priscille Brodin; David Shum
Journal:  Sci Rep       Date:  2022-04-04       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.